As predictive markers in NSCLC, TMB of at least 10 mutations per megabase (≥10 mut/Mb) was identified in 31.8%, sensitizing EGFR mutations in 15.1%, KRAS G12C mutations in 10.5%, MET alterations in 5.4% (exon 14 in 2.4%, focal amplification in 3.2%), and actionable oncogenic fusions in ~5% (ALK 3.0%, RET 1.0%, ROS1 0.9%, NTRK1/2/3 0.1%) of reports (Table 1). This evidence concerns the gene ALK and non-small cell lung carcinoma.